Genentech, Inc.
NEWS
On April 16, Celldex Therapeutics reported that its Phase IIb trial of glembatumumab vedotin (glemba) failed in a trial of metastatic triple-negative breast cancer. Now the company has filed with the U.S. Securities and Exchange Commission (SEC) that it is cutting about 20 percent of staff.
This year’s American Academy of Neurology meeting in Los Angeles has revealed positive news that can benefit patients across a wide variety of indications.
Biogen saw a strong first quarter with 11 percent growth in revenues to $3.1 billion, which were spurred by gains in spinal muscular atrophy (SMA) treatment Spinraza and multiple sclerosis treatment Tecfidera.
Sanofi announced that Elias Zerhouni, head of Global Research and Development, is retiring on June 30. The company has appointed John Reed to replace him as of July 1.
Earlier this month Roche acquired a regenerative therapy program for MS from Inception Sciences and now today Roche’s Genentech announced new data showcasing the efficacy of Ocrevus in relapsing multiple sclerosis (RMS).
GlaxoSmithKline Chief Executive Officer Emma Walmsley continues to hone her leadership team with a hire who will focus on potential research and development deals.
Kineta Chronic Pain signed an exclusive option and license deal with Genentech. The two companies will develop Kineta’s alpha9/alpha10 nicotinic acetylcholine receptor (nAChR) antagonists to treat chronic pain.
The U.S. Food and Drug Administration (FDA) granted Genentech, a Roche company, Breakthrough Therapy Designation for Hemlibra (emicizumab-kxwh) for hemophilia A without factor VIII inhibitors.
Roche announced it had temporarily halted recruiting patients to its Phase II MODUL clinical trial for metastatic colorectal cancer after four patient deaths. The patients were receiving Tecentriq (atezolizumab) in combination with Exelixis’ MEK inhibitor Cotellic (cobimetinib).
JOBS
IN THE PRESS